You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Details for Patent: 11,021,475


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,021,475 protect, and when does it expire?

Patent 11,021,475 protects SOTYKTU and is included in one NDA.

This patent has sixty-seven patent family members in thirty-eight countries.

Summary for Patent: 11,021,475
Title:Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Abstract:Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
Inventor(s):Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski
Assignee:Bristol Myers Squibb Co
Application Number:US16/687,279
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,021,475

To delve into the specifics of the United States Patent 11,021,475, it is crucial to analyze several key aspects, including the patent's subject matter, the claims made, and the broader patent landscape. Here’s a detailed breakdown:

Patent Overview

United States Patent 11,021,475, like any other patent, is a grant of exclusive rights to the patent holder for a specified period, typically 20 years from the filing date of the patent application. This patent would fall under the jurisdiction of the U.S. Patent and Trademark Office (USPTO).

Subject Matter Eligibility

One of the critical aspects of any patent is whether the subject matter is eligible for patent protection. Under U.S. patent law, specifically 35 U.S.C. § 101, patents can be granted for any new and useful "process, machine, manufacture, or composition of matter, or any improvement thereof"[1].

However, the Supreme Court has established that "laws of nature, natural phenomena, and abstract ideas" are not patentable. The Alice/Mayo test is often used to determine if a patent claim is directed to an abstract idea and whether it contains an "inventive concept" that transforms the abstract idea into a patent-eligible application[2].

Claims Analysis

The claims of a patent define the scope of the invention and are crucial for determining what is protected. Here are some key points to consider:

Claim Structure

Patent claims are typically divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[3].

Claim Scope

The scope of the claims can be measured using metrics such as independent claim length and independent claim count. Narrower claims, as indicated by shorter lengths and fewer counts, are often associated with a higher probability of grant and a shorter examination process[3].

Patent Eligibility Under 35 U.S.C. § 101

For the claims of Patent 11,021,475 to be valid, they must pass the Alice/Mayo test. This involves two steps:

  • Step One: Determine if the claims are directed to patent-ineligible subject matter, such as an abstract idea.
  • Step Two: If the claims are directed to an abstract idea, determine if they contain elements sufficient to transform the abstract idea into a patent-eligible application[2].

Patentability Requirements

Besides subject matter eligibility, the invention must also meet other patentability requirements:

Novelty Requirement

The claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[1].

Nonobviousness Requirement

The invention must also be nonobvious, meaning it must not be obvious to a person having ordinary skill in the relevant field at the time of the invention[1].

Examination Process

The examination process at the USPTO plays a significant role in shaping the final claims of a patent. The process tends to narrow the scope of patent claims, both in terms of claim length and claim count, especially when the duration of examination is longer[3].

Continuation Procedures

Patent applicants can use various continuation procedures, such as continuations-in-part, divisional applications, and serialized continuations, to refine their claims and increase the chances of patent grant. These procedures can complicate the calculation of allowance rates but are crucial for navigating the patent landscape[4].

Industry and Technological Context

Understanding the technological field in which the patent operates is essential. For example, patents in fields like pharmaceuticals, biotechnology, and computer software have different challenges and requirements compared to those in mechanical engineering or manufacturing processes[1].

Litigation and Enforcement

Patents can be challenged through various mechanisms, including Inter Partes Review (IPR) and Post-Grant Review (PGR) before the Patent Trial and Appeal Board (PTAB). These proceedings are often faster and less expensive than judicial proceedings and require a lower burden of proof to invalidate patents[1].

Key Takeaways

  • Subject Matter Eligibility: Ensure the patent claims are directed to eligible subject matter under 35 U.S.C. § 101.
  • Claims Analysis: Narrower claims are generally more favorable during the examination process.
  • Patentability Requirements: The invention must be novel and nonobvious.
  • Examination Process: The USPTO examination process can significantly narrow the scope of patent claims.
  • Continuation Procedures: Utilize continuation procedures to refine claims and increase the chances of patent grant.
  • Litigation and Enforcement: Be prepared for potential challenges through IPR or PGR.

FAQs

Q: What is the significance of the Alice/Mayo test in patent law?

A: The Alice/Mayo test is used to determine if a patent claim is directed to an abstract idea and whether it contains an "inventive concept" that transforms the abstract idea into a patent-eligible application.

Q: How do continuation procedures affect the patent examination process?

A: Continuation procedures can refine claims, increase the chances of patent grant, and complicate the calculation of allowance rates, especially when multiple continuations are filed.

Q: What are the key metrics for measuring patent scope?

A: Independent claim length and independent claim count are simple yet effective metrics for measuring patent scope.

Q: Why is the novelty requirement important for patentability?

A: The novelty requirement ensures that the claimed invention is new and not already disclosed in the prior art, thereby preventing the issuance of patents for existing knowledge.

Q: How does the PTAB impact patent enforcement?

A: The PTAB provides a faster and less expensive mechanism for challenging patent validity through IPR and PGR, which can be more advantageous than judicial proceedings for accused infringers.

Cited Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review" (Updated May 28, 2024).
  2. U.S. Court of Appeals for the Federal Circuit, "AI VISUALIZE, INC. v. NUANCE COMMUNICATIONS, INC." (April 4, 2024).
  3. SSRN, "Patent Claims and Patent Scope" by authors (September 29, 2016).
  4. Yale Journal of Law and Technology, "What Is the Probability of Receiving a US Patent?" by authors (accessed January 7, 2025).

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,021,475

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol SOTYKTU deucravacitinib TABLET;ORAL 214958-001 Sep 9, 2022 RX Yes Yes 11,021,475 ⤷  Try for Free TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,021,475

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2922846 ⤷  Try for Free 301238 Netherlands ⤷  Try for Free
European Patent Office 2922846 ⤷  Try for Free CA 2023 00024 Denmark ⤷  Try for Free
European Patent Office 2922846 ⤷  Try for Free PA2023523 Lithuania ⤷  Try for Free
European Patent Office 2922846 ⤷  Try for Free LUC00313 Luxembourg ⤷  Try for Free
European Patent Office 2922846 ⤷  Try for Free 2023C/531 Belgium ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.